Diffuse non-Hodgkin's lymphoma (disorder)
REMoDL-A- A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Acalabrutinib
Year Started: 2021
The REMoDL-A clinical trial evaluates the addition of acalabrutinib to standard of care therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-Cell Lymphoma (DLBCL). As part of the study, original diagnostic FFPE tumour blocks are collected for gene expression profiling and central pathology review using IHC and FISH analysis. Tissue microarray blocks may also be produced if there is sufficient tissue left in the diagnostic FFPE tumour block. ETDA blood samples are collected at baseline before administration of any study drugs and ctDNA blood samples are also collected at 8 different timepoints throughout the study (at baseline, during trial treatment and during follow-up).
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- Outside EU access restriction
Associated Data Type | Procurement Timeframe |
---|---|
Biomarker datasets | > 6 months |
Clinical records | > 6 months |
Followup records | > 6 months |
Imaging data | > 6 months |
Pathology records | > 6 months |
Physiological/biochemical measurements | > 6 months |
Treatment records | > 6 months |
Donor Ethnicity | > 6 months |
Male
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
---|---|---|---|---|---|
Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
Whole blood | -60°C to -85°C | Not applicable | 75% -99% |